Covaxin booster dose increases immune response by 40 times: Bharat Biotech

Bharat Biotech International Limited (BBIL), has announced that BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine, has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. The study has been accepted and published in Nature Scientific Reports, a high impact factor journal.

The study was conducted in ~184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, ~6 months after the primary series of 2 doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, N proteins, and for memory T and B cell responses to demonstrate cell mediated immunity.

For more details, check out the full story on the link below:

Bharat Biotech Says Covaxin Booster Dose Increases Immune Response By 40 Times